Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.0K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.0K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.9K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

652
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
652
SN1 Reaction: Stereochemistry02:15

SN1 Reaction: Stereochemistry

10.5K
This lesson provides an in-depth discussion of the stereochemical outcomes in an SN1 reaction.
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
10.5K
SN1 Reaction: Kinetics02:05

SN1 Reaction: Kinetics

9.7K
In an SN2 reaction, the reaction rate depends on both the type of nucleophile and the substrate. A hindered tertiary alkyl halide is practically inert to the SN2 mechanism despite using a strong nucleophile.
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
9.7K
SN1 Reaction: Mechanism02:25

SN1 Reaction: Mechanism

14.5K
Kinetic studies of ionization of a tertiary halide in a protic solvent suggest that only the substrate participates in the rate-determining step (slow step). The nucleophile is involved only after the slowest step. The SN1 reaction takes place in a multiple-step mechanism. 
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...
14.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Anti-inflammatory and anti-apoptotic effects of fumonisin B1, an inhibitor of ceramide synthase, in a rodent model of splanchnic ischemia and reperfusion injury".

The Journal of pharmacology and experimental therapeutics·2026
Same author

Corrigendum to "Activation of GPR183 by 7α,25-dihydroxycholesterol induces behavioral hypersensitivity through mitogen-activated protein kinase and nuclear factor-κB".

The Journal of pharmacology and experimental therapeutics·2026
Same author

Targeting GPR183 to reduce peripheral sensitization: evidence from rodent and human tissue analyses.

bioRxiv : the preprint server for biology·2026
Same author

Retraction Notice to "The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1" J Pharmacol Exp Ther 311 (2004) 44-50.

The Journal of pharmacology and experimental therapeutics·2026
Same author

P2Y<sub>14</sub> Receptor Antagonists: Piperidine Bioisosteres and Mutagenesis-Supported Molecular Modeling.

ACS pharmacology & translational science·2025
Same author

Contribution of S1pr1 -featured astrocyte subpopulation to cisplatin-induced neuropathic pain in male mice.

Pain·2025

Related Experiment Video

Updated: Feb 16, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

4.0K

Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma.

Salvatore Cuzzocrea1,2, Timothy Doyle2, Michela Campolo1

  • 11 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina , Viale Ferdinando Stagno D'Alcontres, Messina, Italy .

Journal of Neurotrauma
|January 10, 2018
PubMed
Summary

Blocking sphingosine 1-phosphate receptor 1 (S1PR1) with siponimod or TASP0277308 reduced inflammation and protected brain tissue after traumatic brain injury (TBI) in mice. This suggests S1PR1 antagonists are promising neuroprotective strategies for TBI.

Keywords:
CCIS1PR1TBI

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.5K
Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging
11:14

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Published on: April 6, 2014

13.0K

Related Experiment Videos

Last Updated: Feb 16, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

4.0K
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

10.5K
Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging
11:14

Acute Brain Trauma in Mice Followed By Longitudinal Two-photon Imaging

Published on: April 6, 2014

13.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Traumatic brain injury (TBI) triggers secondary inflammation and ischemia in the central nervous system (CNS).
  • Sphingosine 1-phosphate (S1P) receptor modulators offer potential therapeutic avenues for CNS inflammatory conditions.

Purpose of the Study:

  • To investigate the immunomodulatory and neuroprotective effects of S1PR1 antagonists, siponimod and TASP0277308, in a mouse model of TBI.
  • To characterize the impact of S1PR1 blockade on neuroinflammation and tissue damage following TBI.

Main Methods:

  • Controlled cortical impact model of TBI in mice.
  • Administration of siponimod or TASP0277308 (1 mg/kg) intraperitoneally at 1 and 4 hours post-trauma.
  • Assessment of inflammatory markers, immune cell activation, lesion volume, and tissue integrity.

Main Results:

  • S1PR1 antagonists significantly reduced astrocyte and microglia activation, pro-inflammatory cytokine release, and expression of adhesion molecules.
  • Treatment decreased T-cell activation (CD4+, CD8+), reduced lesion size, and preserved tissue architecture, microtubule stability, and neural plasticity.
  • Compounds demonstrated anti-inflammatory and immunomodulatory effects in the TBI model.

Conclusions:

  • Blocking the S1PR1 axis with antagonists is a viable neuroprotective strategy for TBI.
  • Low-dose oral S1PR1 antagonists show potential for mitigating TBI-induced neuropathology.
  • Findings enhance understanding of S1PR1-mediated neuroinflammation in TBI pathophysiology.